Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Lilly breakthrough: Dual treatment clears skin & cuts weight in psoriasis patients

The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula

Indian pharma market grew 10.2% yoy in January 2026

Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise

Roche’s Gazyva hits major milestone in rare kidney disease

Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units

Novartis’ Vanrafia shows promise in slowing kidney decline in IgA nephropathy

Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN

HanchorBio scores first FDA orphan drug tag for gastric cancer therapy

The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients

Beyfortus cuts RSV hospitalizations across two seasons in landmark study

The NIRSE-GAL study, conducted in Galicia, Spain, is the first real-world, population-based investigation of a universal RSV immunization program spanning two consecutive seasons

EU to withdraw Levamisole medicines over risk of rare, deadly brain disorder

The recommendation is based on new data from continuous safety monitoring of medicines in the EU

STADA & Bio-Thera bag European nod for Gotenfia